Status:
COMPLETED
Evaluation of the Technical Feasibility of Testing ct DNA for Homologous Recombination Gene Variants in Metastatic Prostate Cancer.
Lead Sponsor:
University Hospital, Tours
Conditions:
Circulating Tumor DNA
Metastatic Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
Evaluation of technical feasibility for Homologous Recombination (HR) genes variants research on circulating tumor DNA (ctDNA) from plasma and urine of patients with a metastatic prostate cancer.
Detailed Description
The benefit of PARPi has been well established for ovarian (SOLO-1 study) and prostate cancer (PROFOUND study) with defects in the Homologous Recombination Repair (HRR) system due to BRCA1 or BRCA2 va...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Age \> 18 years
- Metastatic prostate cancer
- Archived tissue sample available for testing for somatic variants of HRR genes (including BRCA1/BRCA2)
- Free, informed and signed consent for research
- Non inclusion criteria
- Refusal of blood and urine collection
- Patient cognitively incapable of signing consent to participate in this study
- Patient under guardianship or curatorship
Exclusion
Key Trial Info
Start Date :
August 18 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 18 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05415787
Start Date
August 18 2022
End Date
January 18 2024
Last Update
March 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University hospital
Tours, France, 37044